TY - JOUR
T1 - Dabigatran for catastrophic antiphospholipid syndrome
AU - Sarrate, Edurne
AU - Olive, Alejandro
AU - Morales-Indiano, Cristian
AU - Santos-Gómez, Mireia
AU - Orna, Elisa
AU - Monreal, Manuel
AU - Sorigue, Marc
PY - 2019/10
Y1 - 2019/10
N2 - © 2019 Lippincott Williams and Wilkins. All rights reserved. Vitamin K antagonists (VKA) remain the treatment of choice for catastrophic antiphosphilipid syndrome (CAPS). However, when VKAs do not work for a specific patient, direct oral anticoagulants (DOAC) may be a valid therapeutic alternative. We present a patient with a psychiatric disorder and CAPS who was noncompliant to VKA and low-molecular-weight heparin. He was started on dabigatran and has remained thrombosis-free for 8 years. Due to CAPS he has developed progressive renal failure but dabigatran levels were within the expected range. In conclusion, this case report provides anecdotic evidence that dabigatran may be of use in patients with high-risk APS in whom VKA are not an option.
AB - © 2019 Lippincott Williams and Wilkins. All rights reserved. Vitamin K antagonists (VKA) remain the treatment of choice for catastrophic antiphosphilipid syndrome (CAPS). However, when VKAs do not work for a specific patient, direct oral anticoagulants (DOAC) may be a valid therapeutic alternative. We present a patient with a psychiatric disorder and CAPS who was noncompliant to VKA and low-molecular-weight heparin. He was started on dabigatran and has remained thrombosis-free for 8 years. Due to CAPS he has developed progressive renal failure but dabigatran levels were within the expected range. In conclusion, this case report provides anecdotic evidence that dabigatran may be of use in patients with high-risk APS in whom VKA are not an option.
KW - antiphospholipid syndrome
KW - catastrophic antiphospholipid syndrome
KW - dabigatran
KW - direct oral anticoagulant
UR - http://www.mendeley.com/research/dabigatran-catastrophic-antiphospholipid-syndrome
U2 - 10.1097/MBC.0000000000000848
DO - 10.1097/MBC.0000000000000848
M3 - Article
C2 - 31464688
SN - 0957-5235
VL - 30
SP - 364
EP - 365
JO - Blood Coagulation and Fibrinolysis
JF - Blood Coagulation and Fibrinolysis
IS - 7
ER -